CLAIMS:

1. An antibody or an antigen binding fragment thereof that specifically binds to hOX40L and comprises a heavy chain and a light chain and wherein:

the antibody or antigen binding fragment comprises a V_H domain which comprises:

the HCDR1 sequence of SEQ ID NO:36 or 42;

the HCDR2 sequence of SEQ ID NO:38 or 44; and

the HCDR3 sequence of SEQ ID NO:40 or 46;

and wherein the antibody or antigen binding fragment comprises a V_L domain which comprises:

the LCDR1 sequence of SEQ ID No:50 or 56;

the LCDR2 sequence of SEQ ID NO:52 or 58; and

the LCDR3 sequence of SEQ ID NO:54 or 60.

2. An antibody or antigen binding antigen binding fragment according to claim 1, wherein:

the heavy chain comprises a V_H region having at least 85% identity to the amino acid sequence of SEQ ID No:34; and

the light chain comprises a V_L region having at least 85% identity to the amino acid sequence of SEQ ID No:48.

3. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a V_H domain comprising an amino acid sequence of SEQ ID NO: 34 and comprises a V_L domain comprising an amino acid sequence of SEQ ID NO:48.

4. An antibody or an antigen binding fragment thereof, that specifically binds to hOX40L and comprises a heavy chain and a light chain wherein:

the antibody or antigen binding fragment comprises a V_H domain which comprises:

the HCDR1 sequence of SEQ ID NO:4 or 10;

the HCDR2 sequence of SEQ ID NO:6 or 12; and

the HCDR3 sequence of SEQ ID NO:8 or 14;

and wherein the antibody or antigen binding fragment comprises a V_L domain which comprises:

the LCDR1 sequence of SEQ ID No:18 or 24;

the LCDR2 sequence of SEQ ID NO:20 or 26; and

the LCDR3 sequence of SEQ ID NO: 22 or 28.

5. An antibody or antigen binding antigen binding fragment according to claim 4, wherein:

the heavy chain comprises a V_H region having at least 85% identity to the amino acid sequence of SEQ ID No:2; and

the light chain comprises a V_L region having at least 85% identity to the amino acid sequence of SEQ ID No:16.

6. An antibody or antigen binding fragment according to claim 4 or 5, wherein the antibody or antigen binding fragment comprises a V_H domain comprising an amino acid sequence of SEQ ID NO: 2 and comprises a V_L domain comprising an amino acid sequence of SEQ ID NO:16.

7. An antibody or antigen binding fragment according to any preceding claim comprising first and second copies of said V_H domain and/or first and second copies of said V_L domain.

8. An antibody or antigen binding fragment according to claim 6, comprising a human gamma 4 constant region, optionally comprising a heavy chain constant region which is IgG4 PE, preferably wherein the IgG4 PE constant region comprises a heavy chain constant region of SEQ ID NO:128.

9. An antibody or antigen binding fragment according to any preceding claim, wherein the antibody or antigen binding fragment comprises a kappa light chain, optionally wherein the antibody or antigen binding fragment comprises a kappa light chain comprising a constant region selected from the group consisting of the kappa light chain constant region amino acid sequences of SEQ ID NOs: 136, 138, 140, 142 and 144.

10. An antibody or antigen binding fragment according to any preceding claim which is a fully human antibody.

11. An antibody according to any preceding claim, wherein the antibody comprises a heavy chain and a light chain, the heavy chain amino acid sequence consisting of the sequence of SEQ ID No:62 and the light chain amino acid sequence consisting of the sequence of SEQ ID No:64.

12. A pharmaceutical composition comprising an antibody as defined in any one of claims 1 to 11 or an antigen binding fragment as defined in any one of claims 1 to 10, and a pharmaceutically acceptable excipient, diluent or carrier.

13. A pharmaceutical composition according to claim 12, formulated for parenteral administration selected from intravenous or sub-cutaneous administration.

14. A pharmaceutical composition according to claim 12 or claim 13, further comprising a further therapeutic agent independently selected from the group consisting of rapamycin (sirolimus), tacrolimus, ciclosporin, corticosteroids (e.g. methylprednisolone), methotrexate,

mycophenolate mofetil, anti-CD28 antibodies, anti-IL12/IL-23 antibodies (e.g. ustekinumab), anti-CD20 antibodies (e.g.rituximab), anti-CD30 antibodies (e.g. brentuximab), CTLA4-Fc molecules (e.g. abatacept), CCR5 receptor antagonists (e.g. maraviroc), anti-CD40L antibodies, anti-VLA4 antibodies (e.g. natalizumab), anti-LFA1 antibodies, fludarabine, anti-CD52 antibodies (e.g. alemtuzumab), anti-CD45 antibodies, cyclophosphamide, anti-thymocyte globulins, anti-complement C5 antibodies (e.g. eculizumab), anti-a4b7 integrin antibodies (e.g. vedolizumab), anti-IL6 antibodies (e.g. tocilizumab), anti-IL2R antibodies (e.g. basilixumab), anti-CD25 antibodies (e.g. daclizumab), anti-TNFa / TNFa-Fc molecules (e.g. etanercept, adalimumab, infliximab, golimumab or certolizumab pegol) and Vorinostat.

15. A pharmaceutical composition according to any one of claims 12 to 14, or a kit comprising a pharmaceutical composition as defined in any one of claims 19 to 21, wherein the pharmaceutical composition is for treating and/or preventing a hOX40L-mediated disease or condition selected from an autoimmune disease or condition, a systemic inflammatory disease or condition, or transplant rejection; for example inflammatory bowel disease (IBD), Crohn's disease, rheumatoid arthritis, transplant rejection, allogenic transplant rejection, graft-versus-host disease (GvHD), ulcerative colitis, diabetes, uveitis, ankylosing spondylitis, contact hypersensitivity, and atherosclerosis, in particular GvHD.

16. A pharmaceutical composition according to any one of claims 12 to 14, or a kit comprising a pharmaceutical composition as defined in any one of claims 12 to 14, wherein the pharmaceutical composition is for treating a hOX40L-mediated disease or condition selected from systemic lupus erythematosus (SLE) and multiple sclerosis.

17. A pharmaceutical composition according to any one of claims 12 to 14, or a kit comprising a pharmaceutical composition as defined in any one of claims 12 to 14, wherein the pharmaceutical composition is for treating or preventing dermatitis, asthma, alopecia areata, celiac disease or systemic sclerosis.

18. A pharmaceutical composition according to any one of claims 13 to 18, or kit according to any one of claims 12 to 14, further comprising a label or instructions for use in treating and/or preventing said disease or condition in a human, optionally wherein the label or instructions comprise a marketing authorisation number (e.g., an FDA or EMA authorisation number).

19. A kit according to any one of claims 12 to 18, which comprises an IV or injection device that comprises the antibody or antigen binding fragment thereof.

20. An antibody or antigen binding fragment as defined in any one of claims 1 to 11 for use in therapy.

21. An antibody or antigen binding fragment according to claim 20, for use in treating or preventing a hOX40L-mediated disease or condition selected from an autoimmune disease or condition, a systemic inflammatory disease or condition, or transplant rejection.

22. An antibody or antigen binding fragment for the use according to claim 21, wherein the hOX40L-mediated disease or condition is selected from inflammatory bowel disease (IBD), Crohn's disease, rheumatoid arthritis, transplant rejection, allogenic transplant rejection, graft-versus-host disease (GvHD), ulcerative colitis, systemic lupus erythematosus, diabetes, uveitis, ankylosing spondylitis, contact hypersensitivity, multiple sclerosis and atherosclerosis.

23. An antibody or antigen binding fragment for the use according to claim 21, wherein the hOX40L-mediated disease or condition is dermatitis, asthma, alopecia areata, celiac disease or systemic sclerosis.

24. A nucleic acid that encodes:

(a) a V_H domain and a V_L domain of an antibody or antigen binding fragment as defined in any one of claims 1 to 11; or

(b) a heavy chain and a light chain of an antibody or antigen binding fragment as defined in any one of claims 1 to 11.

25. A nucleic acid that encodes a V_H domain of an antibody as defined in any one of claims 1 to 12 or an antigen binding fragment as defined in any one of claims 1 to 11 and a nucleic acid that encodes a V_L domain of an antibody as defined in any of claims 1 to 12 or an antigen binding fragment as defined in any one of claims 1 to 11.

26. A vector comprising the nucleic acid as defined in claim 24 or 25; optionally wherein the vector is a CHO or HEK293 vector.

27. A host cell comprising the nucleic acid as defined in claim 24 or 27 or the vector as defined in claim 26.

28. Use of a pharmaceutical composition according to any one of claims 12 to 14 in the manufacture of a medicament for treating and/or preventing a hOX40L-mediated disease or condition selected from an autoimmune disease or condition, a systemic inflammatory disease or condition, or transplant rejection; for example inflammatory bowel disease (IBD), Crohn's disease, rheumatoid arthritis, transplant rejection, allogenic transplant rejection, graft-versus-host disease (GvHD), ulcerative colitis, diabetes, uveitis, ankylosing spondylitis, contact hypersensitivity, and atherosclerosis, in particular GvHD.

29. Use of a pharmaceutical composition according to any one of claims 12 to 14 in the manufacture of a medicament for treating a hOX40L-mediated disease or condition selected from systemic lupus erythematosus (SLE) and multiple sclerosis.

30. Use of a pharmaceutical composition according to any one of claims 12 to 14 in the manufacture of a medicament for treating or preventing dermatitis, asthma, alopecia areata, celiac disease or systemic sclerosis.

31. Use of an antibody or antigen binding fragment according to any one of claims 1-11 in the manufacture of a medicament for treating or preventing a hOX40L-mediated disease or condition selected from an autoimmune disease or condition, a systemic inflammatory disease or condition, or transplant rejection.

32. The use according to claim 31, wherein the hOX40L-mediated disease or condition is selected from inflammatory bowel disease (IBD), Crohn's disease, rheumatoid arthritis, transplant rejection, allogenic transplant rejection, graft-versus-host disease (GvHD), ulcerative colitis, systemic lupus erythematosus, diabetes, uveitis, ankylosing spondylitis, contact hypersensitivity, multiple sclerosis and atherosclerosis.

33. The use according to claim 31, wherein the hOX40L-mediated disease or condition is dermatitis, asthma, alopecia areata, celiac disease or systemic sclerosis.